Duff & Phelps Investment Management Co. Sells 610 Shares of Eli Lilly And Co (LLY)

Duff & Phelps Investment Management Co. lessened its holdings in Eli Lilly And Co (NYSE:LLY) by 6.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,510 shares of the company’s stock after selling 610 shares during the period. Duff & Phelps Investment Management Co.’s holdings in Eli Lilly And Co were worth $1,234,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in LLY. Athena Capital Advisors LLC purchased a new position in shares of Eli Lilly And Co during the fourth quarter valued at approximately $26,000. Wakefield Asset Management LLLP purchased a new position in shares of Eli Lilly And Co during the fourth quarter valued at approximately $27,000. Trust Department MB Financial Bank N A lifted its stake in shares of Eli Lilly And Co by 54.7% during the first quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock valued at $30,000 after buying an additional 82 shares during the period. Larson Financial Group LLC purchased a new position in shares of Eli Lilly And Co during the fourth quarter valued at approximately $29,000. Finally, Ironwood Financial llc purchased a new position in shares of Eli Lilly And Co during the fourth quarter valued at approximately $30,000. 84.49% of the stock is currently owned by institutional investors.

In other Eli Lilly And Co news, SVP Stephen F. Fry sold 14,847 shares of the stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $123.16, for a total transaction of $1,828,556.52. Following the transaction, the senior vice president now directly owns 109,663 shares in the company, valued at approximately $13,506,095.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Aarti S. Shah sold 1,800 shares of the stock in a transaction on Friday, April 5th. The shares were sold at an average price of $125.85, for a total transaction of $226,530.00. Following the transaction, the senior vice president now owns 18,425 shares in the company, valued at $2,318,786.25. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 640,959 shares of company stock valued at $81,539,352. Company insiders own 0.11% of the company’s stock.

LLY traded up $1.40 during trading hours on Wednesday, reaching $117.98. 3,893,818 shares of the stock traded hands, compared to its average volume of 12,555,263. The firm has a market cap of $112.63 billion, a price-to-earnings ratio of 21.26, a PEG ratio of 2.06 and a beta of 0.27. Eli Lilly And Co has a fifty-two week low of $81.61 and a fifty-two week high of $132.13. The company has a current ratio of 1.12, a quick ratio of 0.85 and a debt-to-equity ratio of 5.50.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings results on Tuesday, April 30th. The company reported $1.33 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.01. The business had revenue of $5.09 billion during the quarter, compared to analyst estimates of $5.12 billion. Eli Lilly And Co had a net margin of 26.13% and a return on equity of 56.62%. The business’s revenue was up 2.6% on a year-over-year basis. During the same period last year, the business earned $1.31 EPS. On average, analysts forecast that Eli Lilly And Co will post 5.66 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Friday, May 17th will be issued a dividend of $0.645 per share. This represents a $2.58 dividend on an annualized basis and a yield of 2.19%. The ex-dividend date is Thursday, May 16th. Eli Lilly And Co’s payout ratio is 46.49%.

LLY has been the topic of several recent analyst reports. Cantor Fitzgerald reissued a “buy” rating on shares of Eli Lilly And Co in a research note on Monday, February 4th. UBS Group reduced their price objective on shares of Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating on the stock in a research note on Friday, February 8th. BMO Capital Markets upped their price target on shares of Eli Lilly And Co from $130.00 to $133.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 1st. Bank of America set a $129.00 price target on shares of Eli Lilly And Co and gave the stock a “hold” rating in a research report on Thursday, March 21st. Finally, Citigroup set a $124.00 price objective on shares of Eli Lilly And Co and gave the stock a “hold” rating in a research report on Tuesday, February 26th. Eleven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Eli Lilly And Co has a consensus rating of “Buy” and a consensus target price of $118.15.

TRADEMARK VIOLATION WARNING: This piece was published by Sundance Herald and is the property of of Sundance Herald. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://sundanceherald.com/2019/05/22/eli-lilly-and-co-lly-holdings-reduced-by-duff-phelps-investment-management-co.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: Bear Market

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply